News and Announcements
Proteomics International Signs Long-Term Partnership with Dutch/Australian Company BiosanaPharma
- Published July 14, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Proteomics International Laboratories Ltd (ASX:PIQ), has recently announced a long-term partnership with Dutch/Australian company BiosanaPharma to test a new treatment for allergic asthma.
KEY TAKEAWAYS:
- The partnership marks the start of a new service in release testing and long-term and accelerated stability testing for biosimilars, backed by ISO 17035 accreditation.
- Agreement is Proteomics International’s largest biosimilars contract to date with a value in excess of $200,000.
- The global biosimilars drug market surpassed US$ 3.3billion in 2016 and is expected to triple in size to reach US$10.5 billion by 2022 as pharmaceutical companies seek to replicate a host of blockbuster drugs coming off patent.
Dr Lipscombe said stability and accelerated testing for biosimilars was a new area of importance for Proteomics International, with the long-term service attracting long-term clients. “Only specialist laboratories are able to take on this work because if a fridge or freezer fails, due to a power cut for instance, you could lose six months of testing data,” he said. Our extensive ISO 17025 laboratory certifications set us apart as the most accredited protein testing laboratory in the world.
BiosanaPharma’s Chief Operating and Chief Scientific Officer Jaap Wieling remarked that the quality and reliability of service was key to choosing Proteomics International as a partner for their exciting new drug. “Australia’s advanced R&D environment supports our desire to make antibody biosimilars efficiently and affordably,” he said.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
